Shopping Cart

Your shopping cart is currently empty

BzATP triethylammonium salt

Name: BzATP triethylammonium salt
Brand: TargetMol
SKU: TP2226
Price: 41 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Hot

Catalog No. TP2226Cas No. 112898-15-4

BzATP triethylammonium salt is a P2X7 receptor agonist.

BzATP triethylammonium salt

🥰Excellent

Hot

Purity: 99.57%

Catalog No. TP2226Cas No. 112898-15-4

BzATP triethylammonium salt is a P2X7 receptor agonist.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$41	In Stock	In Stock
5 mg	$97	In Stock	In Stock
10 mg	$155	In Stock	In Stock
25 mg	$258	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$179	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.57%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR HPLC

Product Introduction

Bioactivity

Description	BzATP triethylammonium salt is a P2X7 receptor agonist.
Targets&IC50	P2X1:8.74 (pEC50), P2X2:5.26 (pEC50), P2X7 (Rat):3.6 μM, P2X3:7.1 (pEC50), P2X4:6.31 (pEC50)
In vitro	METHODS: Glioma cell lines U87 and U251 were treated with BzATP triethylammonium salt (5-1000 µM) for 2-72 h. Cell proliferation was detected by MTT assay. RESULTS: Proliferation of glioma cell lines U87 and U251 was significantly increased in the presence of BzATP. the peak fine cell proliferation of both U87 and U251 cell lines was 100 µM BzATP, and the optimal incubation time was 24 h for both cell lines [1]. METHODS: Retinal ganglion cells were treated with BzATP triethylammonium salt (50 µM) for 2 min and intracellular Ca2+ levels were measured. RESULTS: The P2X7 agonist BzATP resulted in a rapid increase in intracellular Ca2+ and the level remained elevated for 2 min after agonist application. More than 80% of the examined cells responded strongly to BzATP. [2]
In vivo	METHODS: To investigate the effects on whole-body energy metabolism, BzATP triethylammonium salt (1 mg/kg) was administered intraperitoneally to C57BL/6J mice once daily for seven days. RESULTS: BzATP triethylammonium salt increased metabolic rate and O2 consumption while decreasing respiratory rate and upregulating NADPH oxidase 2 in gastrocnemius and tibialis anterior muscle.The findings suggest that activation of P2X7 has a significant effect on energy homeostasis and muscle metabolism. [3]

Chemical Properties

Molecular Weight	816.59
Formula	C₃₀H₃₉N₆O₁₅P₃
Cas No.	112898-15-4
Smiles	O[C@H]1[C@@H](O[C@@H]([C@H]1OC(C2=CC=C(C=C2)C(C3=CC=CC=C3)=O)=O)COP(OP(OP(O)(O)=O)(O)=O)(O)=O)N4C=NC5=C4N=CN=C5N.CCN(CC)CC
Relative Density.	no data available

Storage & Solubility Information

Storage

store at low temperature,keep away from moisture,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 50 mg/mL (61.23 mM), Sonication is recommended.

DMSO: 50 mg/mL (61.23 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.45 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.2246 mL	6.1230 mL	12.2460 mL	61.2302 mL
5 mM	0.2449 mL	1.2246 mL	2.4492 mL	12.2460 mL
10 mM	0.1225 mL	0.6123 mL	1.2246 mL	6.1230 mL
20 mM	0.0612 mL	0.3062 mL	0.6123 mL	3.0615 mL
50 mM	0.0245 mL	0.1225 mL	0.2449 mL	1.2246 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc